Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $62.43 billion. The enterprise value is $94.54 billion.
| Market Cap | 62.43B |
| Enterprise Value | 94.54B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has decreased by -1.64% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | +1.56% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 50.58% |
| Float | 1.59B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.42 |
| PS Ratio | 2.20 |
| Forward PS | 0.01 |
| PB Ratio | 1.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.78 |
| P/OCF Ratio | 10.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.30, with an EV/FCF ratio of 19.36.
| EV / Earnings | n/a |
| EV / Sales | 3.33 |
| EV / EBITDA | 12.30 |
| EV / EBIT | 24.03 |
| EV / FCF | 19.36 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.14 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 4.26 |
| Debt / FCF | 6.97 |
| Interest Coverage | 3.43 |
Financial Efficiency
Return on equity (ROE) is -2.26% and return on invested capital (ROIC) is 5.13%.
| Return on Equity (ROE) | -2.26% |
| Return on Assets (ROA) | 2.69% |
| Return on Invested Capital (ROIC) | 5.13% |
| Return on Capital Employed (ROCE) | 4.96% |
| Weighted Average Cost of Capital (WACC) | 4.05% |
| Revenue Per Employee | $604,230 |
| Profits Per Employee | -$21,380 |
| Employee Count | 47,029 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.22 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $202.29 million in taxes.
| Income Tax | 202.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.94% in the last 52 weeks. The beta is 0.10, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +40.94% |
| 50-Day Moving Average | 18.28 |
| 200-Day Moving Average | 17.32 |
| Relative Strength Index (RSI) | 66.87 |
| Average Volume (20 Days) | 2,517,497 |
Short Selling Information
The latest short interest is 2.92 million, so 0.18% of the outstanding shares have been sold short.
| Short Interest | 2.92M |
| Short Previous Month | 4.09M |
| Short % of Shares Out | 0.18% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 1.28 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $28.42 billion and -$1.01 billion in losses. Loss per share was -$0.32.
| Revenue | 28.42B |
| Gross Profit | 18.32B |
| Operating Income | 3.93B |
| Pretax Income | -801.42M |
| Net Income | -1.01B |
| EBITDA | 7.69B |
| EBIT | 3.93B |
| Loss Per Share | -$0.32 |
Balance Sheet
The company has $2.84 billion in cash and $34.06 billion in debt, with a net cash position of -$31.23 billion or -$19.76 per share.
| Cash & Cash Equivalents | 2.84B |
| Total Debt | 34.06B |
| Net Cash | -31.23B |
| Net Cash Per Share | -$19.76 |
| Equity (Book Value) | 46.50B |
| Book Value Per Share | 29.42 |
| Working Capital | 2.37B |
Cash Flow
In the last 12 months, operating cash flow was $6.04 billion and capital expenditures -$1.15 billion, giving a free cash flow of $4.88 billion.
| Operating Cash Flow | 6.04B |
| Capital Expenditures | -1.15B |
| Depreciation & Amortization | 3.86B |
| Net Borrowing | -64.76M |
| Free Cash Flow | 4.88B |
| FCF Per Share | $3.09 |
Margins
Gross margin is 64.47%, with operating and profit margins of 13.85% and -3.54%.
| Gross Margin | 64.47% |
| Operating Margin | 13.85% |
| Pretax Margin | -2.82% |
| Profit Margin | -3.54% |
| EBITDA Margin | 27.05% |
| EBIT Margin | 13.85% |
| FCF Margin | 16.71% |
Dividends & Yields
This stock pays an annual dividend of $0.49, which amounts to a dividend yield of 2.53%.
| Dividend Per Share | $0.49 |
| Dividend Yield | 2.53% |
| Dividend Growth (YoY) | -9.35% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| FCF Payout Ratio | 15.90% |
| Buyback Yield | 1.64% |
| Shareholder Yield | 4.17% |
| Earnings Yield | -1.61% |
| FCF Yield | 7.82% |
Analyst Forecast
The average price target for Takeda Pharmaceutical is $22.77, which is 17.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.77 |
| Price Target Difference | 17.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 3.00% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.09 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.09 |
| Piotroski F-Score | 4 |